Fennec Pharmaceuticals

PriceFennec Pharmaceuticals

FENC

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Historical stock price chart and annual return over the past years

-16%

5 years

% Total

FENC
-3%

5 years

Annual Return

FENC